Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.50 +1.96%

+$0.19 today

Market cap
$66.22M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.07M

Average 1.40M

Fair Value & DCF

Compare our fair value with your own assumptions

Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Build your own valuation

Test an independent scenario and compare it with Intrinsic Alpha's estimate.

Sign in to use the DCF calculator

Free accounts get 5 valuations per week. Upgrade for more.

Sign in / Sign up

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+1.5% (5yr)1 analysts
RevenueN/AN/A+23.9%
-5.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
+1.5% (5yr)2 analysts
EBITN/AN/AN/A
+6.5% (5yr)2 analysts

Analysis

Recent growth has been strongest in Revenue at +23.9% over three years. Forward estimates point to EBIT at +6.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Estimates & History

Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.

Further estimates hidden. Sign in to unlock

Competitor Valuations

Peer stocks ranked by intrinsic value status

CompanyMarket CapPriceValuationP/E1Y Return

Ovid Therapeutics Inc.

NASDAQ:OVID

$479.38M$2.54Not rated-7.1+68.18%

Shattuck Labs, Inc.

NASDAQ:STTK

$473.57M$4.65Not rated-10.9+128.36%

InflaRx N.V.

NASDAQ:IFRX

$172.42M$1.17Not rated-2.7-9.45%

Sutro Biopharma, Inc.

NASDAQ:STRO

$162.83M$9.82Not rated-0.0+0.22%

Oramed Pharmaceuticals Inc.

NASDAQ:ORMP

$154.33M$3.71Not rated1.4+66.81%

MacroGenics, Inc.

NASDAQ:MGNX

$140.14M$2.20Not rated-3.6+33.12%

Coya Therapeutics, Inc.

NASDAQ:COYA

$73.42M$3.13Not rated-3.9-50.97%

Champions Oncology, Inc.

NASDAQ:CSBR

$65.49M$4.71Undervalued-41.0-32.97%

Clene Inc.

NASDAQ:CLNN

$56.45M$3.92Not rated-2.1-57.24%

Context Therapeutics Inc.

NASDAQ:CNTX

$16.61M$0.18Not rated-1.5-35.83%